Drug Trial Radar · NCT02720068
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
Last checked: Nov 19, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
481
Actual
Start
May 2, 2016
Primary completion
Mar 15, 2024
Study completion Mar 15, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a safety and pharmacokinetics study of favezelimab as monotherapy and in combination with pembrolizumab AND favezelimab/pembrolizumab as monotherapy in adults with metastatic solid tumors for which there is no available therapy which may convey clinical benefit. Part A of this study is a dose escalation design in which participants receive favezelimab as monotherapy or favezelimab in combination with pembrolizumab. Part B is a dose confirmation design to estimate the recommended Phase 2 dose (RP2D), as determined by dose-limiting toxicity, for favezelimab in combination with pembrolizumab or pembrolizumab and lenvatinib in participants with advanced solid tumors. Part B will also assess the efficacy of favezelimab as monotherapy; favezelimab in combination with pembrolizumab with and without chemotherapy; favezelimab in combination with pembrolizumab and lenvatinib; and favezelimab/pembrolizumab as monotherapy in expansion cohorts. Participants who have completed the initial course of treatment and have investigator-determined progressive disease may be eligible for a second course of an additional 17 cycles of study treatment.
Conditions
- Neoplasms
Interventions
FavezelimabBiological
IV infusion
PembrolizumabBiological
IV infusion
OxaliplatinDrug
IV infusion
IrinotecanDrug
IV infusion
Leucovorin (Calcium Folinate)Drug
IV infusion
Fluorouracil [5-FU]Drug
IV infusion
Favezelimab/PembrolizumabBiological
IV infusion
LenvatinibDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)Time frame: Up to 21 days (Cycle 1)
- Number of Participants Who Experienced an Adverse Event (AE)Time frame: Up to approximately 31.3 months
- Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 28.3 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.